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Abstract
Background: Despite the large number of published papers analyzing the prognostic role of Ki-67 in NSCLC, it is
still not considered an established factor for routine use in clinical practice. The present meta-analysis summarizes
and analyses the associations between Ki-67 expression and clinical outcome in NSCLC patients.
Methods: PubMed, Cochrane, and Embase databases were searched systematically using identical search strategies.
The impacts of Ki-67 expression on survival in patients with NSCLC and NSCLC subtypes were evaluated. Furthermore,
the association between Ki-67 expression and the clinicopathological features of NSCLC were evaluated.
Results: In total, 32 studies from 30 articles met the inclusion criteria, involving 5600 patients. Meta-analysis results
suggested that high Ki-67 expression was negatively associated with overall survival (OS; HR = 1.59, 95 % CI 1.35-1.88,
P < 0.001) and disease-free survival (DFS; HR = 2.21, 95 % CI 1.43-3.42, P < 0.001) in NSCLC patients. Analysis of the
different subgroups of NSCLC suggested that the negative association between high Ki-67 expression and OS and DFS
in Asian NSCLC patients was stronger than that in non-Asian NSCLC patients, particularly in early-stage (Stage I-II)
adenocarcinoma (ADC) patients. Additionally, while high expression was more common in males, smokers, and
those with poorer differentiation, there was no correlation between high Ki-67 expression and age or lymph node
status. Importantly, significant correlations between high Ki-67 expression and clinicopathological features (males, higher
tumor stage, poor differentiation) were seen only in Asian NSCLC patients.
Conclusions: The present meta-analysis indicated that elevated Ki-67 expression was associated with a poorer outcome
in NSCLC patients, particularly in early-stage Asian ADC patients. Studies with larger numbers of patients are needed to
validate our findings.
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Background
Lung cancer (LC) is often fatal and is very common
worldwide. It has been reported that the overall 5-year
survival rate of lung cancer patients was ~16 %, and that it
was < 70 % even in patients diagnosed at stage I [1]. Non-
small cell lung cancer (NSCLC), of which adenocarcinoma
(ADC) and non-ADC (including squamous cell carcinoma
(SQCC), large cell lung carcinoma (LCC), and bronchial
gland carcinoma (BGC)) account for the majority of cases,
represents almost 80 % of primary LC cases. Although the
treatment of LC is becoming more individualized, there is
an urgent need for reliable prognostic factors to predict
clinical outcome and to more precisely stratify the group of
patients with poorer outcomes.
Ki-67 is expressed in proliferating cells and has been
used in clinical practice as an index to evaluate prolifera-
tive activity in NSCLC and other cancers [2, 3]. Moreover,
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several studies have suggested that high Ki-67 expression
in a tumor is a strong prognostic factor in NSCLC [4–7].
However, despite the large number of published papers
analyzing the prognostic role of Ki-67 in NSCLC, it is still
not considered an established factor for routine use in
clinical practice [8, 9]. Although a large meta-analysis
involving 17 studies published in 2004 showed that
high expression of Ki-67 was associated with a poorer
overall survival (hazard ratio (HR) 1.56, 95 % confi-
dence interval (CI) 1.30–1.87), it did not evaluate the
association between Ki-67 expression and disease-free
survival. Most importantly, because of the limited number
of studies and patients included, it did not examine high
Ki-67 expression in Asian patients [2]. Thus, a further
meta-analysis investigation is needed to delineate the rela-
tionship between Ki-67 expression and prognostic signifi-
cance in NSCLC more clearly.
In this study, we performed a meta-analysis to explore
the relationship between Ki-67 expression and its prognos-
tic value in NSCLC. Associations between Ki-67 expression
and the clinicopathological features of NSCLC, including
age, gender, smoking status, lymph node status, and tumor
differentiation, were also evaluated.
Methods
The protocol, including the objective of our analysis, cri-
teria for study inclusion/exclusion, assessment of study
quality, primary outcome, and statistical methods, was in
accordance with the Preferred Reporting Items for Sys-
tematic Reviews and Meta-Analyses (“PRISMA”) state-
ment (Additional files 1 and 2) [10].
Study selection
The PubMed, Cochrane, and Embase databases were
searched systematically for relevant articles published
up to November 1, 2014. Search terms included Non-
Small-Cell Lung Cancer (‘Carcinoma, Non-Small-Cell
Lung’ or ‘Carcinoma, Non Small Cell Lung’ or ‘Carcin-
omas, Non-Small-Cell Lung’ or ‘Lung Carcinoma, Non-
Small-Cell’ or ‘Lung Carcinomas, Non-Small-Cell’ or
‘Non-Small-Cell Lung Carcinomas’ or ‘Carcinoma, Non-
Small Cell Lung’ or ‘Non-Small-Cell Lung Carcinoma’
or ‘Non Small Cell Lung Carcinoma’ or ‘NSCLC’), Ki-67
(‘Ki-67’ or ‘Ki67’ or ‘MIB-1’ or ‘MIB 1’ or ‘proliferative
index’), prognosis, survival, and outcome, in all possible
combinations. Using these parameters, we filtered out
all the eligible articles and looked through their reference
lists for additional studies. The systematic literature search
was undertaken independently by two reviewers (SW and
ZW) and ended in November 2014. Disagreements were
determined through consensus with a third reviewer (CL).
Authors of the eligible studies were contacted for add-
itional data relevant to this meta-analysis, as necessary.
Inclusion and exclusion criteria
Inclusion criteria for the primary studies were 1) inclusion
of patients with a distinct NSCLC diagnosis by pathology,
2) measurement of Ki-67 expression using immunohisto-
chemistry (IHC) in primary NSCLC tissue, 3) investigation
of the relationship between Ki-67 expression and overall
survival (OS) or disease-free survival (DFS) in patients
with NSCLC and availability of valid survival data either
provided directly or that could be calculated indirectly,
and 4) publication in the English language. When authors
had several publications or reported on the same patient
population, only the most recent or complete study was
included.
Exclusion criteria for the primary studies were 1) an
overlap among articles or duplicate data; 2) the use of
animals or cell lines; 3) insufficient data availability for
estimating HR and 95 % CI, such as typical of abstracts,
editorials, letters, conferences data, expert opinions, re-
views, and case reports; 4) investigation of the relationship
between Ki-67 and NSCLC using methods other than IHC;
5) inclusion of patients who underwent chemotherapy
or radiotherapy interventions; and 6) a study sample
comprising fewer than 20 patients.
Data extraction and literature quality assessment
Two investigators (SW and WZ) conducted the data ex-
tractions independently [10]. Any discrepancies were deter-
mined by reviewing the articles together until a consensus
was reached. The following information was extracted from
each article: name of first author and publication date;
study population characteristics such as number of patients,
age, gender, and treatment during follow-up; tumor data
such as pathology, type of NSCLC, Ki-67 expression in the
primary site, and TNM stage; variables such as tissue Ki-67
measurement method, cut-off value for the Ki-67 level; sur-
vival data, such as OS and DFS; and relevant quality scores.
The primary data were the HR and 95 % CI for survival
outcomes, including OS and DFS.
For study quality control, we used the Reporting Rec-
ommendations for Tumor Marker Prognostic Studies
(REMARK) and extracted 18 items (Additional file 3:
Table S1). Each item was scored on a scale of 0–2, with
2 indicating a complete description, 1 indicating a partly
matched description, and 0 indicating no matched de-
scription. The maximum score was 36 [11, 12]. Any
discrepancies were resolved by a consensus discussion
with a third reviewer (CL).
Statistical analysis
ORs with 95 % CIs were used to estimate the association
between Ki-67 expression and the clinical characteristics
of NSCLC patients, including age, gender, smoking habits,
pathological type, TNM stage, tumor stage, lymph nodes
status, and tumor differentiation status. According to the
Wen et al. BMC Cancer  (2015) 15:520 Page 2 of 13
clinical characteristics, stages III and IV together were de-
fined as ‘advanced stage’ and stages I and II as ‘early stage’.
T2, T3, and T4 were all defined as ‘advanced stage’ com-
pared with T1. N1, N2, and N3, which were combined into
one group. Moderately and poorly differentiated were also
combined [13, 14].
To identify the prognostic effect of Ki-67 expression,
the overall HR and 95 % CI were evaluated for elevated
Ki-67 expression. The combined ORs and HRs were ini-
tially estimated graphically using forest plots. Subgroup
analyses were then conducted when the risk (OR or HR)
was significant (P < 0.05).
The heterogeneity of the studies was assessed using
Cochran’s Q test and the Higgins I2 statistic. When the
I2 was below 50 %, the studies were considered to have
acceptable heterogeneity, and a fixed effects model was
used; otherwise, a random effect model was used.
To assess the stability of the results, we performed a
sensitivity analysis in which one study at a time was re-
moved to examine its individual influence on the pooled
HR. Publication bias was evaluated using a funnel plot with
Egger’s and Begg’s tests. P values < 0.05 were considered to
indicate statistically significant publication bias. Addition-
ally, ‘trim and fill’ analyses were used to evaluate the stability
of our meta-analysis results if the plots were asymmetric
[15]. All analyses were performed using the STATA soft-
ware (er. 12.0; Stata Corp., College Station, TX, USA).
Results
Literature search and study characteristics
We identified 2046 potentially relevant articles through
the search strategy described in Methods. As shown in
Fig. 1, 2009 articles were excluded after the first screen-
ing based on the abstracts and/or titles, and 37 articles
remained after reviewing their full texts for relevance.
Seven articles were ultimately excluded, due to overlap
with previously reported studies (n = 4) [16–19], use of
interventional treatments (n = 1) [20], a lack of survival
data (n = 1) [21], or providing RFS other than OS/DFS in
NSCLC (n = 1) [22]. Additionally, two of the articles
could be divided into two studies [23, 24]. Thus, a total
of 30 eligible articles [5–9, 23–47] involving 32 studies
were included in this meta-analysis. The flow diagram of
the study selection procedure is presented in Fig. 1.
As demonstrated in Table 1, 5600 patients with related
clinical data from a total of 6178 patients were enrolled in
the 32 studies, which were published between 1993 and
2014. All 32 studies were retrospective. Of the 32 studies,
11 were conducted in Japan, five in America, four in China,
four in Italy, two in Canada, two in Korea, and one each in
Argentina, Brazil, the Czech Republic, and Germany. The
case size of each study varied from 44 to 494 (median, 156)
patients. The age of the patients ranged from 19 to 89, and
the overall proportion of males was 66.11 %.
All studies included information on disease stage, and
the proportion of stages I + II was 67.9 %. IHC was the
only technique used to detect Ki-67 expression, using
various antibodies and cut-off values (range, 5–50 %),
and 2503 (44.70 %) tissue samples had ‘high’ Ki-67 ex-
pression (Table 1).
Of the 32 studies, 19 provided HR and 95 % CI values
directly, whereas in the other 13 studies, they were calcu-
lated from available data (n = 6) or from Kaplan–Meier
survival curves (n = 7), as described by Tierney [48]. Of
Fig. 1 Flow diagram of the relevant studies selection procedure
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OS/DFS HR (95%CI) Study
Quality
Ahn 2014 Korea 109,20/89 65 65/44 NSCLC I-III Anti-Ki67; 1:50 40 30 OS/DFS,5 S.urves O:1.60(0.74-3.44)
D:2.875(1.326-6.234)
34
Cagini 2000x Italy 99,43/56 66 91/8 NSCLC I-II MIB-1; 1:100 20 41 OS, 5 Events O:1.33(0.72-2.43) 31
D’amico 1999 USA 408,204/204 62.9 269/139 NSCLC I MIB-1, NA 7 60 OS,5 Events O:1.41(0.99-2.00) 33
Demarchi 2000 Brazil 64,32/32 59.8 43/21 ADC I-III MIB-1; 1:400 22.2 51.9 OS,5 R O:0.49(0.20-1.22) 31
Fontanini 1996 Italy 65,31/34 46 63/7 NSCLC I-III MIB-1; 1:200 30.2 45 OS,3 R O:1.05(0.83-1.324) 34
Haga 2003 Japan 187,112/75 NA 120/67 ADC,SCC I MIB-1; 1:100 10 120 OS,5 Events O:3.636(1.267-10.439) 33
Harpole 1996 USA 275,109/106 63 177/98 NSCLC I Anti-Ki67; NA 7 68 OS, 5 Events O:1.53(1.00-2.37) 34
Hayashi 2001 Japan 98,36/62 62.7 56/42 ADC I-III MIB-1; 1:200 12.6 60 OS,5 R O:2.0(1.1-3.8) 29
Hommura 2000 Japan 215,116/99 63.3 144/71 NSCLC I-IV MIB-1; 1:50 30 84 OS,3 R O:2.53(1.35-4.72) 34
Huang 2005 Japan 173,117/56 67 116/57 NSCLC I-III MIB-1; 1:40 25 77 OS,5 Events O:1.56(0.99-2.44) 32
Ishida 1997 Japan 114,57/57 64.9 59/55 ADC I-II MIB-1; 1:50 22.7 28.5 OS,5 S.urves O:8.50(3.52-20.53) 32
Kaira 2008 Japan 361,186/135 67 196/125 NSCLC I-III MIB-1; 1:40 25 48 OS,5 R O:0.667(0.271-1.643) 32
Liu 2012a China 494,113/381 61 366/128 ADC,SCC I-IV Anti-Ki67; 1:200 50 25.9 OS,5 R O:1.583(1.100-2.277) 32
Liu 2012b China 174,88/79 60 133/41 ADC,SCC I-IV Anti-Ki67; 1:200 50 25 OS,5 R O:1.681(0.487-5.797) 32
Maddau 2006 Italy 180,103/77 65.5, 151/29 NSCLC I-III MIB-1; 1:50 25 3-47 OS,3 R O:0.79(0.55-1.15) 29
Mehdi 1998 USA 243,154/49 63.5 184/76 NSCLC I-II MIB-1; 1:150 25 60 OS/DFS,3 S.urves O:1.60(1.06-2.41)
D:1.58(1.06-2.41)
36
Minami 2002 Japan 47,22/25 64 28/19 ADC I MIB-1; NA 20 89 OS,5 R O:1.022(0.96-1.08) 33
Navaratnam
2012a
Canada 79,37/42 69.2 47/32 NSCLC I-II MIB-1; 1:50 20 36 OS,3 R O: 1.81(0.93-3.53) 30
Navaratnam
2012b
Cadana 58,20/38 62.8 23/35 NSCLC I-II MIB-1; 1:50 10 36 OS,3 R O:1.31(0.68-2.52) 24
Nguyen 2000 Czech 89,34/55 60 73/16 NSCLC I-IV MIB-1; NA 30 36 OS,3 S.urves O:2.15(1.21-3.78) 28
Pence 1993 USA 61,15/46 63 56/5 NSCLC I-IV Anti-Ki67; 1:100 PI 3.5 38 OS,5 S. urves O:2.18(1.00-4.78) 29
Poleri 2003 Argentina 50,28/22 60.8 NA ADC,SCC I MIB-1; NA 33 59 DFS,5 Events D:4.10(1.98-8.46) 33
Puglisi 2002 Italy 81,28/53 62.5 NA ADC,SCC I-III MIB-1; 1:100 34.2 115.76 OS,5 R O: 1.29(0.71-2.31) 33
Ramnath 2001 USA 212,118/94 63.7 111/101 NSCLC I-IV MIB-1; 1:100 25 24.3 OS,3 S. Curve O:1.41(0.93-2.12) 31
Shiba 2000 Japan 156,81/75 62.4 112/44 NSCLC I-III MIB-1; 1:100 20 49 OS,5 S. Curve O:2.20(1.38-3.53) 34
Takahashi 2002 Japan 62,22/40 66.9 40/22 ADC,SCC I-II MIB-1; 1:100 25 3.9 DFS,5 R D:1.02(0.32-3.30) 33














Table 1 Characteristics of studies included in the final meta-analysis of Ki-67 expression and prognosis of NSCLC (Continued)
Woo 2009 Japan 184,79/105 67.8 92/92 NSCLC I MIB-1; NA 10 35.9 DFS,5 R D:3.84(1.18-12.45) 34
Wu 2013 China 192,120/72 59 104/88 NSCLC I-III Anti-Ki67; 1:200 10 60 OS/DFS,5 R O:2.829(1.26-4.525)
D:2.929(2.184-4.928)
32
Yamashita 2011 Japan 44,13/31 NA 25/19 NSCLC I Anti-Ki67; 1:100 5 60 DFS,5 R D:12.5(1.1-140.7) 33
Yoo 2007 Korea 219,17/209 65.8 168/51 ADC,SCC I-III Anti-Ki67; NA 30 38.9 OS,5 R O:0.827(0.319-2.140) 36
Zhong 2014 China 270,66/204 62 192/78 ADC,SCC I-III Anti-Ki67; 1:200 50 60 OS,5 R O:2.179(1.096-4.333) 34
Abbreviation: HR hazard ratio, CI confidence interval, OS overall survival, DFS disease-free survival, NSCLC non-small-cell Lung cancer, ADC adenocarcinoma, SCC squamous carcinoma, R Author reported, O, OS, D,DFS,












the 32 studies, 20 identified high Ki-67 expression as an
indicator of poor prognosis, whereas the remaining 12
studies showed no significant effect of high Ki-67 expres-
sion on survival outcome.
Methodological quality of the studies
The results of the quality assessment of the included
studies are shown in Table 1. Quality scores ranged from
24 to 36, with a median value of 33. All of the studies
satisfied most of the items and reported totals for the
assay methods and confounders.
Correlation of high Ki-67 expression with OS in NSCLC
Of the 28 studies investigating the association between
Ki-67 expression and OS, 14 involved Asian patients
(n = 2729) and 14 involved non-Asian patients (n = 2287).
The overall HR and 95 % CI for NSCLC patients was 1.59
(95 % CI 1.35–1.88, P < 0.001, n = 5007), with significant
heterogeneity (I2 = 74.8 %, P < 0.001; Fig. 2, Table 2). Sub-
group analyses showed that the risk was significant in both
Asian and non-Asian patients (HR 1.97, 95 % CI 1.43–
2.71, P < 0.001 and HR 1.37, 95 % CI 1.15–1.64, P = 0.013,
respectively) with significant heterogeneity (I2 = 82.1 %,
P < 0.001 and I2 = 74.0 %, P < 0.001, respectively).
Next, subgroups including TNM stage (eight studies
for stage I, eight for stages I–II, seven for stages I–III,
and one for stages III–IV) and type of NSCLC (10 studies
for ADC and two for non–ADC) were analyzed. The ana-
lyses indicated that high Ki–67 expression was associated
with a shorter OS in stage I, stages I–II, and stages I–III
patients (HR 1.85, 95 % CI 1.27–2.69, P = 0.001; HR 1.72,
95 % CI 1.20–2.46, P = 0.003; and HR 1.60, 95 % CI
1.21–2.12, P = 0.001, respectively) with heterogeneity
(I2 = 78.7 %, P < 0.001; I2 = 76.1 %, P < 0.001; and I2 =
36.5 %, P = 0.001, respectively), but no association with
shorter OS was observed in patients in stages III–IV
(HR 1.31, 95 % CI 0.68–2.53, P = 0.42).
Another subgroup analysis (ADC vs. non–ADC) dem-
onstrated that the ADC group showed a significant asso-
ciation between high Ki–67 expression and shorter OS
(HR 2.21, 95 % CI 1.38–3.50, P < 0.001). However, the
association was not significant in the non-ADC group
(HR 1.88, 95 % CI 0.88–4.01, P = 0.105). Additionally, only
Asian patients (vs. non-Asian patients) and the early-stage
group (stages I–II vs. advanced stage) in the ADC group
Fig. 2 The hazard ratio (HR) of Ki-67 expression associated with OS in all NSCLC patients. HR > 1 implied worse OS for the group with high
Ki-67 expression
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demonstrated significant associations between high Ki–67
expression and shorter OS. The combined HRs were 3.01,
95 % CI 1.96–4.02, P < 0.001 and 3.30, 95 % CI 1.37–7.96,
P = 0.008, respectively. Non-Asian ADC patients and
ADC patients at advanced stages of the disease showed no
significant association between high Ki–67 expression and
OS (HR 1.88, 95 % CI 0.88–4.01, P = 0.359 and HR 1.51,
95 % CI 0.92–2.47, P = 0.102, respectively).
Correlation of high Ki-67 expression with OS in NSCLC
using different cut-off values
Subgroup analysis demonstrated that the risks between
Ki–67 expression and OS were not significant using dif-
ferent Ki-67 cut–off values (10 %, 25 %, 50 %). The
pooled HRs and 95 % CIs were as follows: 1.80 (95 % CI
1.20–2.70) vs. 1.53 (95 % CI 1.28–1.84) for a cut–off
value of 10 %, 1.57 (95 % CI 1.27–1.95) vs. 1.60 (95 % CI
1.22–2.08) for a cut–off value of 25 %, and 1.56 (95 % CI
1.30–1.86) vs. 1.72 (95 % CI 1.27–2.33) for a cut–off
value of 50 % with significant heterogeneities (Additional
file 4: Table S2, Additional file 5: Figure S1, Additional
file 6: Figure S2 and Additional file 7: Figure S3).
Correlation between high Ki-67 expression and DFS in
NSCLC
The pooled HR and 95 % CI for DFS provided in eight
studies was 2.21, 95 % CI 1.43–3.43, P < 0.001, with
heterogeneity (I2 = 75.3 %, P < 0.001; Fig. 3, Table 2).
Subgroup analysis showed that the risk in Asian patients
was higher than that in non-Asian patients, and the
combined HRs and 95 % CIs were as follows: HR 2.78,
95 % CI 1.78–4.34, P < 0.001 and HR 1.83, 95 % CI
1.09–3.06, P = 0.022, respectively. Further subgroup ana-
lysis indicated that the very early stage (stage I) showed
the highest risk, when compared with stages I–II or I–
III, with the following combined HRs and 95 % CIs: HR
4.31, 95 % CI 2.37–7.84, P < 0.001; HR 1.51, 95 % CI
1.02–2.23, P = 0.038; and HR 2.02, 95 % CI 0.97–4.20,
P < 0.06, respectively.
Association between high Ki-67 expression and the
clinicopathological characteristics of NSCLC
In this meta-analysis, clinicopathological features, such as
age, gender, smoking habits, pathological type, lymph node
status, and tumor differentiation grade, as impacted by in-
creased Ki-67 expression were compared on the basis of
the 32 studies. The results of the meta-analysis showed
significant associations between high Ki-67 expression and
being male, smoking habits, being a non-ADC patient,
higher tumor stage (T2-4) and poorer differentiation grade
(moderate or poor); the combined ORs and 95 % CIs were
as follows: OR 1.89, 95 % CI 1.53–2.33, P < 0.001; OR 2.20,
95 % CI 1.72–2.82, P < 0.000; OR 1.88, 95 % CI 1.60–2.22,
P < 0.001; OR 1.46, 95 % CI 1.13–1.88, P = 0.004; and OR
Table 2 HR values of OS and DFS of NSCLC subgroups
Outcome Studies (n) Patients HR 95%CI P value Model H, I2, P value
OS All study 28 4534 1.58 1.33-1.87 0.000 Random 100.02,74.0 %,0.000
Asian 14 2729 1.97 1.43-2.71 0.000 Random 72.62,82.1 %,0.000
Non-Asian 14 2278 1.37 1.15-1.64 0.013 Random 22.99,74.0 %,0.000
Stage I 8 1144 1.85 1.27-2.69 0.001 Random 32.90,78.7 %,0.000
Stage I-II 8 1166 1.72 1.20-2.46 0.003 Random 29.43,76.2 %,0.000
Stage I-III 7 1038 1.60 1.21-2.12 0.001 Fixed 9.44, 36.5 %,0.150
Stage III-IV 1 58 1.31 0.68-2.53 0.42 Fixed -
ADC 10 1327 2.21 1.38-3.50 0.000 Random 64.38,86.0 %,0.000
Asian 6 666 3.01 1.96-4.02 0.000 Random 8.70,42.5 %,0.122
Non-Asian 4 661 1.31 0.74-2.33 0.359 Random 18.38,83.7 %,0.000
Stage I-II 6 446 3.30 1.37-7.96 0.008 Random 45.94,89.1 %,0.000
Stage I-III/IV 4 881 1.51 0.92-2.47 0.102 Random 7.75,761.3 %,0.051
Non-ADC 2 184 1.88 0.88-4.01 0.105 Fixed -
DFS All study 8 1326 2.21 1.43-3.43 0.000 Random 28.35,75.3 %,0.000
Asian 5 591 2.78 1.78-4.34 0.000 Random 4.67,14.4 %,0.323
Non-Asian 3 735 1.83 1.09-3.06 0.022 Random 48.95,77.7 %,0.01
Stage I 3 293 4.31 2.37-7.84 0.000 Fixed 0.79,0.0 %,0.672
Stage I-II 2 265 1.51 1.02-2.23 0.038 Fixed 0.48,0.0 %,0.486
Stage I-III/IV 3 783 2.02 0.97-4.20 0.06 Random 11.69, 82.9 %, 0.0.06
Abbreviation: ADC adenocarcinoma, CI confidence interval, DFS disease-free survival, Fixed, Fixed, Inverse Variance model, H Heterogeneity, HR hazard ratio,
I2 I-squared, OS overall survival, Random, Random, I-V heterogeneity model
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1.47, 95 % CI 1.15–1.88, P = 0.002, respectively. Moreover,
significant associations between Ki–67 and gender (male),
being a non-ADC patient, higher tumor stage, and poorer
differentiation were seen only in Asian NSCLC patients.
The combined ORs and 95 % CIs were as follows: OR
2.18, 95 % CI 1.67–2.81, P < 0.001; OR 2.22, 95 % CI 1.82–
2.70; OR 1.47, 95 % CI 1.12–1.94, P = 0.006; and OR 1.50,
95 % CI 1.15–1.94, P = 0.002, respectively (Table 3).
There was no significant association between Ki–67
expression and age (>60 vs. < 60) or lymph node status
(N1–3 vs. N0); the combined ORs and 95 % CIs were OR
1.08, 95 % CI 0.85–1.37, P = 0.553 and OR 1.01, 95 % CI
0.83–1.22, P = 0.927, respectively (Table 3).
Sensitivity analysis
Sensitivity analysis showed that the pooled HRs of OS
and DFS were similar to those calculated after one study
was removed and the rest were reanalyzed (Additional
file 8: Figure S4 and Additional file 9: Figure S5). More-
over, the HR remained unchanged (HR 1.86, 95 % CI
1.44–2.28, P < 0.001 and HR 2.74, 95 % CI 1.25–4.22,
P < 0.001, respectively) after the ‘trim and fill’ method
was used (Additional file 10: Figure S6 and Additional
file 11: Figure S7). Additionally, we report the combined
HR and 95 % CI results of the fixed effects model: pooled
HR 1.86, 95 % CI 1.44–2.28, P < 0.001 for OS and pooled
HR 1.52, 95 % CI 1.08–1.96, P < 0.001 for DFS. These
values were consistent with the random-effects model.
Both analyses support the reliability of our results.
Publication bias
Begg’s test indicated no publication bias among the studies
included in the current meta-analysis regarding the HRs of
OS and DFS, with P values of 0.395 and 0.902, respectively.
Egger’s test indicated no publication bias for DFS (P = 0.34),
but it showed seemingly significant publication bias for OS
after assessing the funnel plot (P < 0.001; Fig. 4).
Discussion
Ki-67 is a nuclear non-histone protein first identified
30 years ago [2]. Because it is expressed during all phases
of the cell cycle except the resting stage (G0), it has been
used as a marker to evaluate proliferation in NSCLC [5, 9,
33, 44], as well as in other tumors, such as lymphoma
[13], esophageal cancer [49], breast cancer [10], and pros-
tate cancer [50]. Nonetheless, studies examining the rela-
tionship between Ki-67 expression and NSCLC prognosis
have been inconsistent [33, 35, 42, 45].
Meta-analytic techniques using non-randomized con-
trolled trials (NRCTs) may be useful in certain clinical
Fig. 3 The hazard ratio (HR) of Ki-67 expression associated with DFS in all NSCLC patients. HR > 1 implied worse OS for the group with high
Ki-67 expression
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settings where the number or the sample size of the
RCTs is insufficient [48]. The results of the current meta-
analysis revealed that high Ki-67 expression in patients
with NSCLC was associated with a poorer prognosis for
OS (HR 1.59, 95 % CI 1.35–1.88, P < 0.001), consistent
with a previous meta-analysis, published in 2004 [2], but
in this case with nearly three–fold as many patients and
double the number of studies. In addition, it was first
reported that high Ki-67 expression in NSCLC patients
was associated with a poor survival outcome for DFS
(combined HR 2.21, 95 % CI 1.43–3.43, P < 0.001). Sen-
sitivity analysis suggested that the association between
high Ki-67 expression and NSCLC prognosis was stable
and unchanged after removing any one study. Also, the
results of the current meta-analysis show that high Ki-67
expression was more common in males (OR = 1.89, P <
0.001), smokers (OR = 2.20, P < 0.001), those in later tumor
stages (OR = 1.46, P = 0.004), or those with poorer differen-
tiation (OR = 1.47, P = 0.002), which has been linked to
more aggressive tumors. Overall, the results of the current
meta-analysis suggest that increased Ki-67 expression
exerts a significantly adverse effect on the prognosis of
NSCLC patients. To our knowledge, this study is the most
comprehensive and detailed meta-analysis to evaluate the
association between Ki-67 expression and survival in
NSCLC patients.
NSCLC is a malignancy displaying substantial hetero-
geneity, and the clinical and biological characteristics of
the different subtypes of NSCLC vary substantially [51].
In this meta-analysis, high Ki-67 expression was a valuable
indicator both of OS and DFS for ADC; this is consistent
with the latest large-scale study conducted by Warth and
colleagues, which included 1482 patients [47]. Further-
more, higher Ki-67 expression was a more valuable indica-
tor for early (stages I–II) NSCLC and early (stages I–II)
ADC. However, it showed no association between survival
and being a non-ADC patient, with a HR of 1.88 and a
95 % CI of 0.88–4.01 for OS. Due to the strict inclusion
criteria, only two studies in the current meta-analysis were
included, and several studies without enough survival data
were excluded. However, several types of non-ADC in-
cluding squamous cell carcinoma (SQCC), large cell lung
carcinoma (LCC), and bronchial gland carcinoma (BGC)
may make it difficult to obtain reliable results. The associ-
ation between high Ki-67 expression and survival outcome
in non-ADC patients still requires further investigation.
It was reported that Asian ethnicity is a favorable
prognostic factor for OS in NSCLC and is independent
of smoking status [52, 53]. However, no data regarding
the impact of Ki-67 and race/ethnicity on the outcome
of NSCLC patients are available. Subgroup analysis in
this study showed that higher Ki-67 expression indicated a
poorer outcome in Asian NSCLC patients compared with
non-Asian patients (HR 1.97, 95 % CI 1.43–2.71 vs. HR
1.37, 95 % CI 1.15–1.64 for OS and HR 2.78, 95 % CI 1.78–
4.34 vs. HR 1.83, 95 % CI 1.09–3.06 for DFS). To date, there
has been no consensus regarding the significance of Ki-67
in NSCLC in Asian versus non-Asian NSCLC patients. In
the current study, a strong relationship was established be-
tween poor prognostic indicators and Ki-67 expression only
in Asian patients. In addition, high Ki-67 expression was as-
sociated with larger tumor size and differentiation, which is
in line with previous studies [2]. Furthermore, we found
higher Ki-67 expression levels in Asian patients compared
Table 3 OR values for NSCLC subgroups according to clinical characteristics
Outcome of interest Studies Patients OR 95%CI P value Model H, I2, P value
Age (>60 vs. <60) n = 6 1531 1.08 0.85-1.37 0.553 Fixed 5.37,6.9 %,0.37
Gender (Male vs. Female) n = 11 2696 1.89 1.53-2.33 0.000 Fixed 10.52,5.0 %,0.40
Asian n = 8 1933 2.18 1.67-2.81 0.000 Fixed 5.97,0.0 %,0.54
Non-Asian n = 3 763 1.38 0.96-1.99 0.084 Fixed 0.97,0.0 %,0.61
Smoke habits(Smoke vs. Non-smoke) n = 7 1785 2.20 1.72-2.82 0.000 Fixed 4.77,0.0 %,0.57
Non-ADC vs. ADC n = 15 3185 1.88 1.60-2.22 0.000 Fixed 17.13,18.3 %,0.25
Asian n = 10 2345 2.22 1.82-2.70 0.000 Fixed 3.81,0.0 %,0.92
Non-Asian n = 5 840 1.31 0.98-1.75 0.073 Fixed 4.74,15.6 %,0.32
T2-4 vs T1 n = 9 2156 1.46 1.13-1.88 0.004 Fixed 3.13,0.0 %,0.93
Asian n = 7 1938 1.47 1.12-1.94 0.006 Fixed 2.86,0.0 %,0.83
Non-Asian n = 2 218 1.37 0.71-2.65 0.349 Fixed 0.23,0.0 %,0.63
N1-3 vs N0 n = 11 2443 1.01 0.83-1.22 0.927 Fixed 10.73,6.8 %,0.38
Differentiation (well vs. moderate/poor) n = 9 2029 1.47 1.15-1.88 0.002 Fixed 6.04,0.0 %,0.64
Asian n = 7 1837 1.50 1.15-1.94 0.002 Fixed 5.14,0.0 %,0.53
Non-Asian n = 2 192 1.28 0.60-2.74 0.517 Fixed 0.81,0.0 %,0.37
Abbreviation: ADC adenocarcinoma, CI confidence interval, Fixed, Fixed, Inverse Variance model, H Heterogeneity, I2 I-squared, OR,odds Ratio
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with non-Asian patients (31.39 % vs. 26.77 %, Additional
file 12: Table S3), whereas no positive patients/total patients
ratio differences were demonstrated (44.91 % vs. 47.18,
P = 711). Therefore, the alteration of Ki-67 expression
may contribute to the differences in the tumor biology
observed between Asian and non-Asian patients with
NSCLC. Although, future validation and investigations
are needed, these data may provide new insights into
biological aggressiveness of NSCLC in Asian versus in
non-Asian patients.
Heterogeneity was significant in this meta-analysis,
and it could not be ruled out by using a random-effects
model or multiple subgroup analyses. For reasons of
homogeneity, we analyzed only the studies dealing with
NSCLC histology and restricted the analysis to the
histological subtypes or tumor stages for which we had
sufficient numbers of studies. Furthermore, the tech-
nique(s) used to identify the expression of Ki-67 can be a
potential source of bias. The use of different antibodies
(anti-Ki67 mAb or anti-MIB-1 mAb) and a protocol to
count the number of cells stained by these antibodies
without a received standard antibody concentration may
yield variation among the studies. Moreover, the cut-off
value used to define a tumor with ‘positive’ Ki-67 staining
is often arbitrary and varies according to the investigator,
from a low percentage to more than 50 %. Martin et al.
[2] introduced two cut-off levels for defining Ki-67 expres-
sion in tumors, one to exclude patients with slowly prolif-
erating tumors due to chemotherapeutic protocols (10 %)
and one to identify patients sensitive to chemotherapy
protocols (25 %). In addition, Warth et al. introduced
50 % as the cut-off value for defining Ki-67 expression in
SQCC [47]. In this study, the adverse effect of high Ki-67
expression on OS showed similar results using these three
recommended cut-off values (Additional file 4: Table S2,
Additional file 5: Figure S1, Additional file 6: Figure S2
and Additional file 7: Figure S3). Nonetheless, a consensus
for the optimal cut-off value for Ki-67 needs to be reached
and validated in NSCLC patients in future studies.
It is important to note that the current study encountered
difficulties, similar as most meta-analysis. First, it was based
on summary data rather than data from individual patients.
Therefore, multivariate analyses for confounding factors
such as histological subtypes, gender and smoking status
were not performed. A meta-regression model that ad-
justed for those factors that were found to be correlated
Fig. 4 Funnel Plots of Begg’s and Egger’s were used to detect publication bias on OS and DFS. Begg’s funnel plots showed seemingly
publication bias on OS (A) while Egger’s funnel plots showed no publication bias on OS in all NSCLC. It showed no publication bias on DFS in
Begg’s test (C) and Egger’s test (D)
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with high K-67 levels was also not performed, too. Sec-
ond, our search was limited to published studies and
excluded unpublished trials or results in abstract form,
which may have led to publication bias. Third, the un-
equal number of studies from Asian countries, with
data derived mainly from Japan, China, and Korea may
have also been a source of bias. Hence, our analysis
may reflect outcomes from East Asia rather than from
Asia in general.
There are several advantages to this study. First, large
numbers (32 studies and 5600 patients) were analyzed,
whereas only 17 studies and 1863 NSCLC patients were
considered in the meta-analysis published in 2004. Second,
important clinical parameters including age, gender, tumor
stage, histology, and race/ethnicity were included in the
analysis. The association between high Ki-67 expression
and DFS was also investigated. However, as several limita-
tions still exist, the results need to be interpreted cautiously.
First, the number of included studies and included NSCLC
patients were relatively small. Moreover, heterogeneity was
inevitable among the groups due to the impossibility of
matching patient characteristics across all studies. This may
have weakened the results to some extent. Second, publica-
tion bias was unavoidable for clinical evidence, because the
relevant data were extracted from non-randomized con-
trolled trials. Third, reports in languages other than English
were excluded; therefore, potential language bias may have
been present. Lastly, some data for OS were extracted from
survival curves or other available data rather than provided
directly. Although the method used for extrapolation of
HRs and 95 % CIs is widely accepted and we did not iden-
tify any major differences in current study (Additional file
13: Figure S8), we could not completely eliminate inaccur-
acy in the extracted survival rates.
Conclusions
Despite these limitations, our systematic review of the
literature showed that high expression of Ki-67 in NSCLC
patients, particularly during the early stages (stages I–II),
in Asians, and in ADC patients is a poor prognostic indi-
cator for survival outcome. Further adequately designed
prospective studies with standardization of the immuno-
histochemistry technique, especially standardization of the
cut-off threshold value, need to be conducted to confirm
these results.
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